Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension of Fx-005 Evaluating Long-Term Safety and Clinical Outcomes of Fx-1006A in Transthyretin Amyloid Polyneuropathy
2008-001262-87Phase 2Completed
- Sponsor
- FoldRx Pharmaceuticals
- Start
- Apr 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tafamidis in familial amyloid polyneuropathy (FAP), sponsored by FoldRx Pharmaceuticals. Primary endpoints: Long-term safety and tolerability of Fx-1006A and Pharmacodynamic stabilization of V30M transthyretin. Started Apr 2008; status: completed.
02
Drugs
tafamidis
03
Conditions
familial amyloid polyneuropathy (FAP)
Beyond the preview
Go deeper on 2008-001262-87.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001262-87.